Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 3
2007 1
2008 1
2009 2
2010 1
2011 1
2012 2
2013 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience.
Guo S, Reddy CA, Kolar M, Woody N, Mahadevan A, Deibel FC, Dietz DW, Remzi FH, Suh JH. Guo S, et al. Radiat Oncol. 2012 Jul 20;7:110. doi: 10.1186/1748-717X-7-110. Radiat Oncol. 2012. PMID: 22817880 Free PMC article.
BACKGROUND: Patients with locally advanced or recurrent rectal cancer often require multimodality treatment. Intraoperative radiation therapy (IORT) is a focal approach which aims to improve local control. ...
BACKGROUND: Patients with locally advanced or recurrent rectal cancer often require multimodality treatment. Intraoperative radiation
PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP, Reddy CA, Garcia J, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, Klein EA. Ciezki JP, et al. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):512-7. doi: 10.1016/j.ijrobp.2005.07.960. Epub 2005 Oct 6. Int J Radiat Oncol Biol Phys. 2006. PMID: 16213667
Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?
Klein EA, Ciezki J, Kupelian PA, Mahadevan A. Klein EA, et al. Urol Oncol. 2009 Jan-Feb;27(1):67-71. doi: 10.1016/j.urolonc.2008.04.001. Urol Oncol. 2009. PMID: 19111801 Review.
Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
Tendulkar RD, Reddy CA, Stephans KL, Ciezki JP, Klein EA, Mahadevan A, Kupelian PA. Tendulkar RD, et al. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1397-404. doi: 10.1016/j.ijrobp.2011.04.042. Epub 2011 Jun 12. Int J Radiat Oncol Biol Phys. 2012. PMID: 21665379
METHODS AND MATERIALS: We identified 585 patients who met HR criteria by 2010 National Comprehensive Cancer Network guidelines, who were treated with EBRT consisting of 74 Gy from 1996 to 2008 at Cleveland Clinic, of whom 95% received ADT. We analyzed biochemical re …
METHODS AND MATERIALS: We identified 585 patients who met HR criteria by 2010 National Comprehensive Cancer Network guidelines, who were tre …
Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
Tendulkar RD, Hunter GK, Reddy CA, Stephans KL, Ciezki JP, Abdel-Wahab M, Stephenson AJ, Klein EA, Mahadevan A, Kupelian PA. Tendulkar RD, et al. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):94-9. doi: 10.1016/j.ijrobp.2013.05.044. Int J Radiat Oncol Biol Phys. 2013. PMID: 23920389
METHODS AND MATERIALS: A total of 660 patients with high-risk prostate cancer were treated with definitive high-dose external beam radiation therapy ( 74 Gy) and androgen deprivation (AD) between 1996 and 2009 at a single institution. Cox proportional hazards regression an …
METHODS AND MATERIALS: A total of 660 patients with high-risk prostate cancer were treated with definitive high-dose external beam radiat
Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Khuntia D, et al. Cancer. 2004 Mar 15;100(6):1283-92. doi: 10.1002/cncr.20093. Cancer. 2004. PMID: 15022298 Free article.
BACKGROUND: The objective of the current study was to report biochemical recurrence-free survival (bRFS) rates among men with T1-T3 prostate carcinoma who were treated with external-beam radiotherapy (RT) at the Cleveland Clinic Foundation (Cleveland, OH). ME …
BACKGROUND: The objective of the current study was to report biochemical recurrence-free survival (bRFS) rates among men with T1-T3 prostate …
Aggressiveness of familial prostate cancer.
Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA. Kupelian PA, et al. J Clin Oncol. 2006 Jul 20;24(21):3445-50. doi: 10.1200/JCO.2006.05.7661. J Clin Oncol. 2006. PMID: 16849760
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Kupelian PA, et al. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30. doi: 10.1016/j.ijrobp.2007.01.067. Epub 2007 Jun 4. Int J Radiat Oncol Biol Phys. 2007. PMID: 17544601
METHODS AND MATERIALS: The study sample included all 770 consecutive patients with localized prostate cancer treated with hypofractionated intensity-modulated radiotherapy at the Cleveland Clinic between 1998 and 2005. The median follow-up was 45 months (maximum, 86 …
METHODS AND MATERIALS: The study sample included all 770 consecutive patients with localized prostate cancer treated with hypofractionated i …
Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function.
Pahlajani G, Raina R, Jones JS, Burdick M, Ali M, Li J, Mahadevan A, Ciezki J, Zippe C. Pahlajani G, et al. BJU Int. 2010 Nov;106(10):1524-7. doi: 10.1111/j.1464-410X.2010.09343.x. BJU Int. 2010. PMID: 20477827 Free article.
The mean age in the early PDE-5i group was 64.8 years, and was 66.0 years in the no-PDE-5i group. The mean radiation dose in the early PDE-5i group was 50.2 Gy, and 43.9 Gy in the other group (P= 0.08). ...
The mean age in the early PDE-5i group was 64.8 years, and was 66.0 years in the no-PDE-5i group. The mean radiation dose in the earl …
A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
Ciezki JP, Klein EA, Angermeier K, Ulchaker J, Chehade N, Altman A, Mahadevan A, Reddy CA. Ciezki JP, et al. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1347-50. doi: 10.1016/j.ijrobp.2004.05.067. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590163
METHODS AND MATERIALS: During 1996-2001, 1668 patients with low- and intermediate-risk prostate cancer were treated at The Cleveland Clinic Foundation. Only patients with a minimum of 2 years of prostate-specific antigen follow-up were included in the analysis, and …
METHODS AND MATERIALS: During 1996-2001, 1668 patients with low- and intermediate-risk prostate cancer were treated at The Cleveland
12 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback